Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial

In the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in the HIV-1-infected subjects who received a recombinant Ad5 HIV-1 gag vaccine. To identify individuals with initial viral suppression (plasma HIV-1 RNA set point

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2012-03, Vol.7 (3), p.e34134
Hauptverfasser:	Li, Jonathan Z, Brumme, Chanson J, Lederman, Michael M, Brumme, Zabrina L, Wang, Hongying, Spritzler, John, Carrington, Mary, Medvik, Kathleen, Walker, Bruce D, Schooley, Robert T, Kuritzkes, Daniel R
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adult AIDS AIDS vaccines AIDS Vaccines - therapeutic use Antiretroviral drugs Biological evolution Biological products industry Biological response modifiers Biology CD4 antigen CD4 Lymphocyte Count CD4-Positive T-Lymphocytes - cytology Clinical trials Comparative analysis Control CTLA-4 Antigen - biosynthesis CTLA-4 protein Cytokines - biosynthesis Durability Evolution Female Flow cytometry Flow Cytometry - methods gag Gene Products, Human Immunodeficiency Virus - genetics Health aspects HIV HIV-1 - genetics Human immunodeficiency virus Humans Immune response Immune System Interferon Interruption Lymphocytes Lymphocytes T Male Medicine Middle Aged Molecular Sequence Data Nucleotide sequence PD-1 protein Placebos Programmed Cell Death 1 Receptor - biosynthesis Reproducibility of Results Ribonucleic acid RNA Sequence Analysis, DNA Suppressors T cells Treatment Outcome Tumor necrosis factor-α Vaccines Vaccines, Synthetic - therapeutic use Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in the HIV-1-infected subjects who received a recombinant Ad5 HIV-1 gag vaccine. To identify individuals with initial viral suppression (plasma HIV-1 RNA set point
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0034134